SCHEMBL24423701

SCHEMBL24423701

CC1CCC(NC(=O)C2CCNCC2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.69
MAPK1 P28482 1/20 0.53
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 1/20 0.49
EPHX1 P07099 3/20 0.48
EPHX2 P34913 1/20 0.47
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
TSHR P16473 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016778 0.90 POLB (0.83) POLBMAPK1ALDH1A1EPHX1EPHX2
Hydrochloric Acid SCHEMBL1999078 0.88 POLB (0.80) POLBMAPK1ALDH1A1EPHX1EPHX2
SCHEMBL17133529 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL517408 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL15431468 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL7159674 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL10080421 0.86 POLB (0.91) POLBMAPK1ALDH1A1EPHX1EPHX2
SCHEMBL14985440 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL7159673 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1
SCHEMBL15199105 0.86 MAPK1 (0.60) POLBMAPK1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD POLB 992/4885MAPK1 1659/4885NPC1 408/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD POLB 2032/4885MAPK1 1393/4885NPC1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.